Edition:
United States

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

84.31USD
22 Jun 2017
Change (% chg)

$1.67 (+2.02%)
Prev Close
$82.64
Open
$82.94
Day's High
$84.76
Day's Low
$82.94
Volume
1,617,895
Avg. Vol
1,052,020
52-wk High
$86.71
52-wk Low
$64.25

Latest Key Developments (Source: Significant Developments)

Eli Lilly and Co files for potential three-part notes offering
Thursday, 4 May 2017 08:42am EDT 

May 4 (Reuters) - Eli Lilly And Co : :Eli Lilly and Co files for potential three-part notes offering; size undisclosed .  Full Article

Incyte Q1 loss per share $0.96
Thursday, 4 May 2017 07:00am EDT 

May 4 (Reuters) - Incyte Corp :Incyte reports 2017 first-quarter financial results and updates on key clinical programs.Q1 revenue $384 million versus i/b/e/s view $360.1 million.Q1 loss per share $0.96.Q1 earnings per share view $-1.00 -- Thomson Reuters I/B/E/S.Incyte corp - Olumiant(®) (baricitinib) approved by european commission for treatment of moderate to severe active rheumatoid arthritis.Incyte corp - incyte and lilly disagree with fda's complete response letter for baricitinib.Incyte corp - expects that lilly will now engage with fda to discuss agency's concerns and determine a potential path forward.Incyte corp - novartis anticipates submitting an nda for capmatinib, incyte's potent and selective c-met inhibitor, in 2018.  Full Article

Eli Lilly and Co sets Q2 2017 dividend of $0.52 per share
Monday, 1 May 2017 02:45pm EDT 

May 1 (Reuters) - Eli Lilly and Co ::Sets quarterly dividend of $0.52 per share.  Full Article

Eli Lilly says got civil investigative demand from Washington AG's office about pricing of insulin products
Monday, 1 May 2017 12:17pm EDT 

May 1 (Reuters) - Eli Lilly And Co :Lilly says got civil investigative demand from washington ag's office about pricing of insulin products, relationships with pharmacy benefit managers.Lilly says got civil investigative demand from state of new mexico's office of the attorney general relating to pricing of insulin products - sec filing.  Full Article

Lilly Q1 non-GAAP earnings per share $0.98
Tuesday, 25 Apr 2017 06:25am EDT 

April 25 (Reuters) - Eli Lilly And Co ::Lilly reports first-quarter 2017 results.Q1 revenue $5.228 billion versus I/B/E/S view $5.21 billion.Sees FY 2017 earnings per share $2.60 to $2.70.Q1 non-GAAP earnings per share $0.98.Q1 loss per share $0.10.Sees FY 2017 revenue $21.8 billion to $22.3 billion.Q1 earnings per share view $0.96 -- Thomson Reuters I/B/E/S.Eli Lilly And Co - qtrly Cymbalta sales $174.6 million versus $198.7 million.For Q1 of 2017, Alimta generated worldwide revenue of $489.9 million, which decreased 13 percent.Fy2017 earnings per share view $4.11, revenue view $22.11 billion -- Thomson Reuters I/B/E/S.Worldwide Jardiance revenue during q1 of 2017 was $74.0 million, an increase of 94 percent.Eli Lilly And Co - "Lilly's new product launches, including trulicity and taltz, led company to a strong quarter of volume-driven revenue growth".Eli Lilly And Co - in Q1 of 2017, company recognized an acquired in-process research and development charge of $857.6 million.On a non-GAAP basis, company has reaffirmed 2017 EPS to be in range of $4.05 to $4.15.Eli Lilly - recognized acquired in-process research and development charge of $857.6 million in quarter associated with acquisition of colucid pharmaceuticals.Eli Lilly and Co - in q1 of 2016, company recognized asset impairment, restructuring and other special charges of $131.4 million.Says in Q1 2017, recognized asset impairment, restructuring and other special charges of $213.9 million.  Full Article

Novartis CEO says takeover prices have risen, focusing on early-stage targets
Tuesday, 25 Apr 2017 01:57am EDT 

April 25 (Reuters) - Novartis Ag :CEO Joe Jimenez says thinks with Cosentyx "we can hold our own" against lilly drug taltz.Says price of potential acquisitions has increased, prompting company to "go upstream" for early stage drug acquisitions.Jimenez says Entresto on track for the objectives for the year, expects growth quarter-by-quarter.Jimenez says timing of Novartis's involvement in Turkey campaign was unfortunate, but principle of supporting patients around the world remains, declined to comment on plans for campaign.  Full Article

Lilly says phase 3 MONARCH 3 breast cancer study of Abemaciclib demonstrated superior progression-free survival at interim analysis
Monday, 24 Apr 2017 06:45am EDT 

April 24 (Reuters) - Eli Lilly And Co ::Lilly announces phase 3 monarch 3 breast cancer study of Abemaciclib demonstrated superior progression-free survival at interim analysis.Eli Lilly and Co- trial met its primary endpoint of demonstrating statistically significant improvement in progression-free survival.Eli Lilly and Co - following monarch 3 interim analysis, Lilly intends to begin global submissions of these results in q3 of 2017.Eli Lilly and Co- intends to initiate monarch 1 and monarch 2 submissions beginning in q2 of 2017.Says adverse events were generally consistent with previous studies of abemaciclib.Eli Lilly and Co - detailed efficacy and safety results for monarch 3 will be presented at a medical meeting in second half of year.Eli Lilly and Co - improvement was shown in a key secondary endpoint of objective response rate (orr) in trial.  Full Article

U.S. FDA issues CRL for baricitinib
Friday, 14 Apr 2017 09:00am EDT 

Incyte Corp : U.S. FDA issues complete response letter for baricitinib . Letter indicates that FDA is unable to approve application in its current form . Specifically, FDA indicated that additional clinical data are needed to determine most appropriate doses . FDA also stated that additional data are necessary to further characterize safety concerns across treatment arms . "Companies disagree with agency's conclusions" . Incyte is evaluating impact of complete response on its previously-issued milestone and research and development expense guidance for 2017 .Lilly is reaffirming both its financial guidance for 2017 and its mid-term guidance for remainder of this decade.  Full Article

Eli Lilly says Lilly Endowment Inc reports open market sale of 210,000 of stock
Friday, 31 Mar 2017 12:16pm EDT 

Eli Lilly And Co :Lilly Endowment Inc reports open market sale of 210,000 of co's common stock on march 30 at $84.674 per share - SEC filing.  Full Article

Intelgenx Technologies says Eli Lilly granted Versafilm exclusive license for tadalafil film product under erectile dysfunction dosing patent
Tuesday, 28 Mar 2017 08:10am EDT 

Intelgenx Technologies Corp : Intelgenx Technologies- Eli Lilly granted Intelgenx' Versafilm exclusive license for tadalafil film product under erectile dysfunction dosing patent . Intelgenx Technologies Corp - any exclusivity associated with tadalafil compound patent expiring is not affected by this agreement - SEC filing . Intelgenx Technologies- exclusive license allows co to commercialize tadalafil ed versafilm product in U.S. prior to expiration of '166 dosing patent Source: (http://bit.ly/2nvYskj) Further company coverage: [IGX.V] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

More From Around the Web

BRIEF-Eli Lilly and Co sets quarterly dividend of $0.52 per share

* Sets quarterly dividend of $0.52per share Source text for Eikon: Further company coverage: